Compare Gold Fields Limited (GFI) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs Regeneron Pharmaceuticals Inc — how do they compare? Gold Fields Limited trades at $37 (market cap $31.87B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× Gold Fields Limited's market cap, and Gold Fields Limited pays the higher dividend (6%). Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 49 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| GFI | REGN | |
|---|---|---|
Market Cap | $31.87B | $76.14B |
Volume | 4,169,651 | 500,239 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $852.03 |
52-Week Low | $31.25 | $557.73 |
Typical Hold Time | 49 Days | 107 Days |
Enterprise Value | $32.47B | $70.85B |
Dividend Yield | 6% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.05, down 3.1% amid market reaction to its rejected $27 billion takeover bid for Northern Star. The stock shows strong fundamentals with a P/E of 7.14, robust 38.66% net margin, and record 2025 revenue of $8.75B. Technical indicators are bearish with moving averages signaling sell pressure, though RSI suggests potential oversold conditions. Recent earnings show mixed results with one beat and three misses against expectations.
The outlook remains positive with analyst consensus target of $52.75 (51% upside) and no sell ratings. Key risks include acquisition execution challenges and gold price volatility. The company's strong cash flow generation ($3.77B operating cash flow) and shareholder returns ($1.25B program) support long-term value despite near-term acquisition uncertainty.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
